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Abstract
Background—Whether left ventricular hypertrophy (LVH) is determined by similar genomic 
and environmental risk factors with stroke, or is simply an intermediate stroke marker, is unknown. 
We present a research plan and preliminary findings to explore the overlap in the genomic and 
environmental determinants of LVH and stroke among Africans participating in the Stroke 
Investigative Research and Education Network (SIREN) study.
Methods—SIREN is a transnational, multi-centre study involving acute stroke patients and age, 
ethnicity and sex-matched controls recruited from 9 sites in Ghana and Nigeria. Genomic and 
environmental risk factors and other relevant phenotypes for stroke and LVH are being collected 
and compared using standard techniques.
Results—This preliminary analysis included only 725 stroke patients (mean age 59.1±13.2 
years; 54.3% males). Fifty- five percent of the stroke subjects had LVH with greater proportion 
among women (51.6% vs 48.4%, p<0.001). Those with LVH were younger (57.9±12.8 vs 
60.6±13.4; p=0.006) and had higher mean systolic and diastolic BP (167.1/99.5 mmHg vs 
151.7/90.6 mmHg, p <0.001). Uncontrolled blood pressure (BP) at presentation was prevalent in 
subjects with LVH (76.2% vs 57.7%; p <0.001). Significant independent predictors of LVH were 
age, < 45 years (AOR =1.91, 95% CI: 1.14 to 3.19), female gender (AOR = 2.01; 95% CI:1.44 to 
2.81), and diastolic BP > 90mmHg (AOR = 2.10; 95% CI:1.39 to 3.19, p <0.001).
Conclusion—The prevalence of LVH was high among stroke patients especially the younger 
ones suggesting a genetic component to LVH. Hypertension was a major modifiable risk factor for 
stroke as well as LVH. It is envisaged that the SIREN project will elucidate polygenic overlap (if 
present) between left ventricular hypertrophy and stroke among Africans, thereby defining the role 
of LVH as a putative intermediate cardiovascular phenotype and therapeutic target to inform 
interventions to reduce stroke risk in populations of African ancestry.
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INTRODUCTION
Stroke is one of the leading causes of mortality and morbidity globally(1) and Africa has a 
significant burden with about 86% of all stroke deaths worldwide occurring in African and 
other low and middle income countries.(2) Cardiovascular disease (CVD), particularly 
hypertension, has become a significant source and contributor to the global disease burden. 
Of the 10 predominant modifiable risk factors accounting for 90% of stroke risk, 
hypertension is the strongest and most common.(3)
Hypertension is also a major determinant of left ventricular hypertrophy (LVH) which is a 
remodeling response to elevated blood pressure. Blacks have a higher prevalence of LVH 
compared to their Caucasian counterparts.(4, 5) The Dallas Heart Study, a population-based 
study, showed that LVH was 2- to 3-fold more common in black men and women versus 
white; such ethnic disparities are present in both normotensives and hypertensives. (4) 
Studies providing genomic explanation for these disparities are not conclusive. Pleiotropy is 
a phenomenon in which a genetic variation, usually a mutation in a single gene locus, affects 
multiple observable apparently non-related phenotypic traits may account for some of these 
overlaps and disparity.(6) Pleiotropic Genetic variation in NPY1R, NPY2R, NPY5R, CPE, 
IL15, and SFRP2, identified in hypertensive siblings, has been found to associate with LV 
phenotypes in blacks and/or whites.(7)
Electrocardiographic parameters such as Cornell product or QRS-complex product can be 
used to detect the presence of LVH. A number of genes associated with these two clinical 
parameters are also positively associated with cardiovascular diseases such as stroke has 
been identified. (8)
The diverse genomic variation of African population (9–11) provides a unique avenue for 
exploring novel genes and molecular independent or dependent pathways of stroke and LVH 
that could lead to better understanding of management options for stroke within the African 
and global populations.
There is an urgent need to accurately determine the current burden of LVH and stroke, and 
fully characterize and quantify the environmental and genetic factors underlying this 
epidemic in Africa. This is pertinent because an association between LVH and stroke has 
been reported (12), but the influence of genetics on this association is yet to be elucidated in 
the African environment (Figure 1). Currently, there are few genomic studies done involving 
African populations.(13) The Stroke Investigative Research Education and Network 
(SIREN) study seeks to address this knowledge gap. SIREN is strategically situated to 
explore a unique black African population to detect genetic determinants of LVH and stroke 
with the potential to identify novel genes and/or gene variants that predispose to alterations 
in left ventricular geometry and consequent stroke.
The understanding of the genomics of LVH and stroke among Africans would aid the 
preventive and interventional strategies in curtailing the burgeoning stroke epidemic in the 
region. We aim to identify, quantify, and compare the socio-demographic and clinical risk 
factors for stroke and LVH among Black Africans.
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We present preliminary findings and a research plan to explore if there are significant 
overlaps in the genomic and environmental determinants of LVH and stroke among Africans 
participating in the SIREN study.
METHODS
Study design
The study rationale and design has been described elsewhere.(14) The SIREN study is a 
multi-centre case-control study involving several sites in northern and southern Nigeria and 
northern and southern Ghana, which has been running since August 2014, with a targeted 
initial recruitment of 3000 cases and 3000 controls. Ethical approval was obtained from all 
study sites and informed consent was obtained from all subjects. Cases included 
consecutively recruited consenting adults (aged 18 years or older) with first clinical stroke 
within 8 days of current symptom onset or ‘last seen without deficit’ with cranial CT or MRI 
scan performed to confirm diagnosis within 10 days of symptom onset. We excluded those 
with stroke mimics, primary subarachnoid hemorrhage and previous strokes, which were not 
ascertained radiologically.
We collected basic demographic and lifestyle data including ethnicity and native language of 
the subjects and their parents, socioeconomic status, dietary patterns, routine physical 
activity, stress depression, cigarette smoking, and alcohol use as well as cardiovascular and 
anthropometric measurements using standard instruments. A detailed neurologic evaluation 
was conducted to assess neurologic deficits and determine stroke severity using the National 
Institute of Health Stroke Severity Score.(15) Stroke outcome was assessed using modified-
Rankin Scale (mRS), at 1 month. Blood samples were collected from cases and controls at 
baseline for measurement of fasting lipid profile, blood glucose and HbA1c. Stroke 
diagnosis and phenotyping were based on clinical evaluation and brain neuroimaging (brain 
CT or MRI).
Hypertension was defined as sustained systolic BP>140mmHg or diastolic BP>90mmHg 
after onset of stroke, a history of hypertension, or taking antihypertensive medications 
before stroke. (14) Diabetes mellitus was defined based on previous history of diabetes 
mellitus, use of medications for diabetes mellitus, fasting glucose levels > 126mg/dl and/or 
HBA1c > 6.5%. (16) Dyslipidemia was defined in accordance with the recommendations of 
the US National Cholesterol Education Program as a high fasting serum total cholesterol 
>=200 mg/dl or High Density lipoprotein (HDL)<=40 mg/dl(17) or Low Density 
Lipoprotein (LDL)>=130 or Triglyceride(Trig) ≥ 150 mg/dl or history of use of statins 
before stroke. Smoking status was characterized as never, former, or current smoker. We 
defined current smokers as individuals who smoked any tobacco in the past 12 months and 
included those who had quit within the past year. Former smokers were defined as those who 
had quit more than a year earlier. Alcohol intake was categorized into never or former 
drinker, moderate drinker (1–30 drinks per month), drinker of more than 30 drinks per 
month, or binge drinker (>5 drinks per day at least once per month).(3, 18) Obesity was 
assessed using body-mass index and waist hip ratio. (3, 18) Individuals were classified as 
sedentary if they were not involved in exercise (including walking, cycling, or gardening) or 
strenuous exercise (jogging, football, and vigorous swimming) before the stroke.(3, 18)
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Electrocardiography
A standard (resting) 12-lead ECG was obtained in each subject by using a ECG acquisition 
box Model MGY-S3, Made in Germany and CONTEC® Workstation Model CONTEC 
EC8000G, Made in China at 25 mm/s and 1mV/cm calibration. Various parameters such as 
PR interval, QRS duration and axis, rate, rhythm, types of arrhythmia and QT intervals were 
measured. LVH was diagnosed using the following criteria: Sokolow-Lyon voltage (sum of 
the amplitudes of S wave in V1 and R wave in V5 or V6 ≥3.5 mV), sex-specific Cornell 
voltage (sum of the amplitudes of S wave in V3 and R wave in aVL2.0 mV in women and 
2.8 mV in men), and Cornell product [(RaVL + SV3) + 8mm for women] × QRS duration ≥ 
2440 mm. The preliminary results below were based on LVH criteria above.
DNA extraction
Thirty-five milliliters of whole blood was obtained using Vacutainer EDTA tubes, kept on 
ice and refrigerated at each peripheral study site. This is subsequently transferred to the 
Genomic Laboratory at Ibadan, Nigeria and the Molecular facilities at the Clinical Virology 
Laboratory, Department of Microbiology, University of Ghana Medical School Accra, 
Ghana and the Genomic Laboratory, Kumasi, Ghana for processing. Genomic DNA is 
extracted from whole blood with Gentra Systems PUREGENE DNA purification kit (Qiagen 
Group), and then checked for purity by determining the optical density with a nanodrop 
spectrophotometer which ensures that the DNA samples are of high purity with a 260/280 
ratio 1.8–2.0 and 260/230 ratio >1.5. The PUREGENE kit allows between 5000–15,000ng 
DNA to be extracted from 300μl of whole blood and also has a protocol to degrade any RNA 
present in elute. In order to avoid degradation of DNA, all DNA samples will be stored in 
aliquots at −20°C in Ghana and shipped to Ibadan, Nigeria on dry ice for long term storage 
at −80 °C in the Central SIREN Biobanking facilities. All subjects’ biosamples are given 
unique barcode identifications.
Genotyping and GWAS Protocol
Genotyping will be performed using the versatile and unique H3Africa Genome Wide 
Linkage Analysis Study (GWAS) Array with over 700,000 African variants as well as 
diverse cardiometabolic and stroke related variants aiming to achieve >80% coverage of 
SNPs with a minor allele frequency (MAF)≥5% across the genome. We will also explore 
candidate SNPs to be selected from SNPs previously associated with stroke or LVH (Tables 
S1–S5). We will explore pathways within the frame work for the interaction among 
cardiovascular risk factors, cardiac diseases and stroke in Africa and beyond. (Figure 1)
The samples used for the customized candidate gene and GWAS analysis will achieve a chip 
wide call rate of >98%. SNPs will be excluded if the minor allele frequency (MAF) is < 0.01 
or fail the Hardy-Weinberg Equilibrium (HWE) test of p< 1 × 10−3. Also, sample or SNPs 
with missing rate greater than 10% will not be considered for further analysis. Population 
structure will be checked using the AWClust algorithm (19) and corrected in association 
analysis. Further, high inflation in QQ plot is also indicative of the evidence of structure.(20)
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Sample size estimation and power justification
We have 99.65% power to detect at least one causal SNP with Genetic Relative Risk (GRR) 
of 1.5, with allele frequency as low as 0.04 for and 87.42% power to detect all 20 causal 
variants alpha level of 0.05 in GWAS setting with multiple test correction.
Data management and statistical analysis
All phenotype data collected from SIREN sites were transmitted to a secure data 
management and storage system at the Medical University of South Carolina. Neuroimaging 
data were processed using the SIREN ACCESS software (Patent Registration Number: 
NG/PT/NC/2016/2007).
For the current analysis of phenotype data, descriptive statistics, univariate analysis and 
logistic regression were performed at p <0.05 to explore risk factors common to both stroke 
and LVH. For categorical variables, the Z-test for proportions was used to compare the risk 
factors between stroke survivors with and without LVH. Independent t-test was performed 
for continuous variables. Furthermore, among stroke survivors with LVH, similar analyses 
were conducted to investigate differences by to stroke type (Ischemic vs Hemorrhagic). In 
order to identify the independent predictors of LVH, variables with p<0.1 in the bivariate 
analyses were entered into a logistic regression model from which Odds Ratio (95% CI) 
were estimated. Model fit was ascertained using the Hosmer-Lemeshow test.
Association analysis with genetic data will be performed using the PLINK software 
package.(21) Data files will be subsequently uploaded into a secure internet site to be 
accessed by study collaborators for analysis. Analysis tools provided in the MetaCore 
software suite developed by GeneGo (www.genego.com) will be used for pathway and 
network-based analysis (22) following identification of relevant pathways related to the 
neurobiology of LVH and stroke. The goal of the pathway and network-based analysis is to 
determine if SNP variants associated with LVH and stroke tend to cluster in biological 
pathways or networks that are of significance to stroke. The set-based method in 
PLINKv1.07 will be used to assess pathways of significance.(21)
PRELIMINARY RESULTS (from ECG LVH and stroke risk factors)
Of all the stroke subjects (n =725), 54.7 % had LVH with greater proportion among women 
(51.6% vs 48.4%; p<0.001).(Table 1) Stroke subjects with LVH were younger (57.9±12.8 
vs. 60.6± 13.4; p=0.006), had higher proportion of uncontrolled blood pressure at 
presentation (76.2% vs 57.7%; p<0.001), and a mean systolic and diastolic blood 
pressure(167.1/99.5 vs 151.7/90.6 mmHg; p<0.001) (Tables 1 and 2).
Over one third of the participants were diabetic while 73.4% and 22.9% of them were 
dyslipidemic and obese respectively. The use of tobacco and heavy alcohol were not 
common. Patients with hemorrhagic stroke had a greater proportion of Sokolow Lyon LVH 
(52.8 vs 31.8%; p<0.001), while the Cornell product LVH prevalence were comparable. 
Patients with hemorrhagic stroke with LVH were younger (53.0±11.5 vs 59.9 ±13.2 yrs.) 
with higher SBP and DBP (177.3/107.3mmHg vs 160.7/95.4 mmHg; p<0.001), while a 
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greater proportion of ischemic stroke were diabetic (44.8% vs 29.3%; p=0.008) and had 
prior cardiac disease (18.8% vs 10.3%;p=0.05).(Table 2).
Significant independent predictors of LVH found were age < 45 years (AOR =1.91, 95% CI: 
1.14 to 3.19), p= 0.014), female gender (AOR = 2.01; 95% CI:1.44 to 2.81, p <0.001) and 
diastolic blood pressure > 90mmHg (AOR = 2.10; 95% CI:1.39 to 3.19, p <0.001) as shown 
in Table 3.
DISCUSSION
In this current study, more than half of the stroke patients had LVH with female 
preponderance. Hypertension was the major modifiable risk factor for both stroke and LVH. 
Depending on the study design and location, the prevalence of LVH in hypertensive patients 
ranges from 36%–41%.(23) Our findings of LVH of 55% was higher than earlier studies 
which reported 38% (24, 25) and 40%(24) in US black populated community and Japanese 
population respectively. This was lower than 80% in Houston cocaine users cohort.(26) The 
inconsistency in the prevalence underscores the influence of genomics and environment on 
LVH and stroke; persons with African ancestry are more prone to LVH and stroke.(27)
An interesting finding in the study is the female preponderance which is contrary to the male 
predominance in a previous study.(28) In that same study, however, LVH by Cornell voltage-
duration product criteria was predominantly associated with female gender, whereas 
presence of ECG LVH by Sokolow-Lyon voltage criteria was predominantly related to male 
gender, and black race. The gender disparity was therefore inconclusive. Some other studies 
have reported the gender disparity in cardiovascular morbidity and mortality.(29, 30) Similar 
to our finding, female blacks have been reported to have more LVH than Caucasians. (31, 
32)
In our study, greater than a third of the participants were diabetic while 73.4% and 22.9% of 
them were dyslipidemic and obese respectively. Diabetes was not significantly correlated 
with presence of LVH but it was significantly associated with ischaemic stroke. This was the 
same finding in INTERSTROKE (16) and EUROSTROKE(36). Case-control studies of 
stroke patients and prospective epidemiological studies in other diverse populations have 
also confirmed an independent effect of diabetes with a relative risk of ischemic stroke in 
persons with diabetes from 1.8 to 3. (5) This has been attributed to increased susceptibility 
to atherosclerosis and increased prevalence of atherogenic risk factors such as hypertension, 
obesity, and abnormal blood lipids in diabetics.
In our study dyslipidemia was not significantly associated with LVH, nor was it associated 
with ischaemic stroke just as it was reported in EUROSTROKE(36). A direct link between 
hypercholesterolemia and ischemic stroke has not been established, despite a confirmed 
positive relationship with carotid atherosclerosis. The established benefit of statins have also 
been in prevention of secondary strokes, not primary events as in our study. (5)
Current smoking was not significantly associated with LVH or stroke type in our study. The 
number of smokers was however very small, 2.5%, and this could explain the non-
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significance. In EUROSTROKE(36), for instance, smokers comprised of 41.4 – 41.9% of 
stroke cases.
Presence of LVH in stroke has been shown to increase the risk of repeat stroke and other 
cardiovascular events.(33, 34) While certain hypotheses have been given to explain why 
LVH predisposes for coronary heart disease and death(35), the mechanisms for stroke have 
not been conclusive.
Strengths and limitations
This is the largest exploration of the interactions among vascular risk factors, LVH and 
stroke among Africans to date. The preliminary findings support the exploration of genomic 
investigation into the contribution and relationship of LVH and stroke among African 
Blacks. It also provides a unique opportunity to identify genes associated with LVH, stroke 
or both. This would also serve as a chance to compare the genetic constitution of West 
African blacks in respect with LVH and stroke with other racial databases.
Finally, this study would enhance the multi-dimensional strategy for combating the 
burgeoning epidemic of stroke in Sub-Saharan Africa.
Some potential challenges include those associated with equipment due to poor health care 
infrastructure and frequent power outages. Efforts have been made to ensure all centres 
collaborating in this study have at least a CT scan or MRI machine, ECG machine, and 
echocardiography machine with a trans-thoracic transducer. To address power outages, 
alternative would be utilized while for the equipment breakdown, the sites utilize private 
facilities which are readily available and nearby. Solar powered freezers are also available to 
keep blood samples in all the collaborating centres.
Controls were not included in this preliminary analysis which limit our ability to infer the 
association between LVH and stroke. Echocardiography findings were also not included in 
this analysis. More detailed analysis will be performed after recruitment of the initial 3000 
case control pairs.
CONCLUSION
LVH affects over half of the African patients with stroke, especially females. The 
preponderance of LVH in the younger patients with stroke suggests genetic underpinnings 
which we plan to unravel within the SIREN study. Cardiovascular risk factors especially 
hypertension may serve as intermediate phenotypes for both LVH and stroke. Understanding 
these interactions could provide multiple targets for reducing the increasing stroke among 
individuals of African ancestry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Left ventricular hypertrophy(LVH) was found in more than half of African 
stroke patients.
• LVH was more common in the younger ones suggesting a genetic component.
• Hypertension was a major modifiable risk factor for stroke as well as LVH
• SIREN will elucidate polygenic overlap between LVH and stroke among 
Africans.
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Figure 1. 
Framework for the interaction among cardiovascular risk factors, cardiac diseases, and 
stroke in Africa and beyond.
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Table 3
Independent predictors of LVH among stroke patients
Variables AOR (95% CI) p-value
Baseline Age group (years)
 18 – 45 1.91 (1.14–3.19) 0.014
 46 – 65 1.35 (0.93–1.95) 0.116
 > 65 1.00
Female gender 2.01 (1.44–2.81) <0.001
Average SBP >140 1.08 (0.62–1.87) 0.788
Average DBP > 90 2.10 (1.39–3.19) <0.001
Hypertension 1.73 (0.71–4.24) 0.228
Mean Arterial Blood Pressure 1.01 (0.99–1.02) 0.061
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